Arjun D. Sinha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Arjun D. Sinha has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Aaron Ganci
Department of Visual Communication Design, Herron School of Art and Design, Indiana University, Indianapolis, IN, United States
2 shared publications - Cynthia L. Russell
School of Nursing and Health Studies, University of Missouri-Kansas City, United States
2 shared publications - James H. Hill
Indiana University - Purdue University Indianapolis, Indianapolis, IN, USA
2 shared publications - K. Denise Kerley
Department of Infection Prevention, Indiana University Hospital, Indianapolis, IN
2 shared publications - Rebecca J. Bartlett Ellis
School of Nursing Indiana University Indianapolis Indiana USA
2 shared publications - Sadiya Sana Khan
Northwestern University Feinberg School of Medicine
2 shared publications
Latest Publications
- 15 September 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21  (1) , 172-182
Barriers and Opportunities in Access to Peritoneal Dialysis across Veterans Health Administration
Peritoneal dialysis (PD) use among the US Veteran population is lower than in the non-Veteran kidney failure population. Enhancing access to PD within the Veteran Health Administration (VHA) may be crucial for achieving the Advancing American Kidney Health Executive Order goals. The VHA Home Dialysis Committee conducted a nationwide survey of nephrology stakeholders to assess Veterans' access to PD across the VHA and identify barriers and opportunities for the growth of VHA-affiliated PD services. Participants were invited through email and completed an electronic questionnaire consisting of 17 PD access items and 15 respondent characteristic items. Of the 141 eligible centers, 117 (83%) responded, including 97 facilities that provide nephrology services. Respondents indicated that PD could ideally serve 25% (interquartile range, 15%–40%) of Veterans with kidney failure. Most (62%) of the nephrology service-providing centers offered outpatient hemodialysis; however, only 28% reported providing outpatient PD services, with a median census of 10 Veterans. Among those lacking, 30% expressed a desire to establish outpatient PD services. The availability of comprehensive KRT-directed prekidney failure education, an inpatient PD program, or respondents' perceptions of Veteran interest in PD were positively associated ( P < 0.05) with their desire to establish outpatient PD services. System-related challenges, such as limited space and capital costs of establishing a program, alongside staff-related issues such as insufficient availability of trained nurses and support staff, were frequently cited barriers to PD programs. Respondents commonly cited the need for formal VHA-specific policies and procedural standards, administrative guides to establish local PD and patient education programs, and VHA-based PD nurse training assistance as strategies to address PD underutilization. Our findings suggest that the Veterans' lack of access to VHA-based PD programs may be an underrecognized barrier to their PD utilization. VHA nephrology stakeholders have a high desire to establish PD services but require local and system-based support to address PD underuse across the VHA.
- 15 September 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21  (1) , 172-182
Barriers and Opportunities in Access to Peritoneal Dialysis across Veterans Health Administration
Peritoneal dialysis (PD) use among the US Veteran population is lower than in the non-Veteran kidney failure population. Enhancing access to PD within the Veteran Health Administration (VHA) may be crucial for achieving the Advancing American Kidney Health Executive Order goals. The VHA Home Dialysis Committee conducted a nationwide survey of nephrology stakeholders to assess Veterans' access to PD across the VHA and identify barriers and opportunities for the growth of VHA-affiliated PD services. Participants were invited through email and completed an electronic questionnaire consisting of 17 PD access items and 15 respondent characteristic items. Of the 141 eligible centers, 117 (83%) responded, including 97 facilities that provide nephrology services. Respondents indicated that PD could ideally serve 25% (interquartile range, 15%–40%) of Veterans with kidney failure. Most (62%) of the nephrology service-providing centers offered outpatient hemodialysis; however, only 28% reported providing outpatient PD services, with a median census of 10 Veterans. Among those lacking, 30% expressed a desire to establish outpatient PD services. The availability of comprehensive KRT-directed prekidney failure education, an inpatient PD program, or respondents' perceptions of Veteran interest in PD were positively associated ( P < 0.05) with their desire to establish outpatient PD services. System-related challenges, such as limited space and capital costs of establishing a program, alongside staff-related issues such as insufficient availability of trained nurses and support staff, were frequently cited barriers to PD programs. Respondents commonly cited the need for formal VHA-specific policies and procedural standards, administrative guides to establish local PD and patient education programs, and VHA-based PD nurse training assistance as strategies to address PD underutilization. Our findings suggest that the Veterans' lack of access to VHA-based PD programs may be an underrecognized barrier to their PD utilization. VHA nephrology stakeholders have a high desire to establish PD services but require local and system-based support to address PD underuse across the VHA.
- Open Access
- 6 December 2024
- Published by Patrick M. Magoon Institute for Healthy Communities in Journal of Health Advocacy
Getting into Good Trouble: A case study on getting started in organized physician advocacy
The Good Trouble Coalition (GTC) was established in 2022 by healthcare and public health practitioners in Indiana, aiming to channel frustration into action amidst the politicization of public health issues during the COVID-19 pandemic. This paper focuses on the origins of GTC, detailing the motivations behind its formation, particularly the need to counter legislative attacks on public health and the patient-doctor relationship. It outlines the critical steps required to establish a nonprofit advocacy group, including gathering a multidisciplinary team, creating a mission statement, incorporating as a 501(c)(4), and securing funding and resources. Key actions taken by GTC in its first year include publishing an open letter against abortion bans, organizing legislative testimonies, engaging with media, and holding public protests. By sharing GTC’s journey, the paper aims to provide a roadmap for other healthcare professionals and public health workers interested in organizing for civic advocacy and promoting health equity.
- 6 December 2024
- Published by Patrick M. Magoon Institute for Healthy Communities in Journal of Health Advocacy
Open AccessGetting into Good Trouble: A case study on getting started in organized physician advocacy
The Good Trouble Coalition (GTC) was established in 2022 by healthcare and public health practitioners in Indiana, aiming to channel frustration into action amidst the politicization of public health issues during the COVID-19 pandemic. This paper focuses on the origins of GTC, detailing the motivations behind its formation, particularly the need to counter legislative attacks on public health and the patient-doctor relationship. It outlines the critical steps required to establish a nonprofit advocacy group, including gathering a multidisciplinary team, creating a mission statement, incorporating as a 501(c)(4), and securing funding and resources. Key actions taken by GTC in its first year include publishing an open letter against abortion bans, organizing legislative testimonies, engaging with media, and holding public protests. By sharing GTC’s journey, the paper aims to provide a roadmap for other healthcare professionals and public health workers interested in organizing for civic advocacy and promoting health equity.
- 12 June 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19  (8) , 1025-1032
Mechanisms of Antihypertensive Effect of Chlorthalidone in Advanced Chronic Kidney Disease
Key Points: Chlorthalidone reduces the amount of fluid and the BP, but fluid volume reduction is not the cause of lowering of BP. It is not volume loss but the response to volume loss such as the synthesis of substances that lower BP is important. Background: Chlorthalidone (CTD) in a chronic kidney disease randomized trial demonstrated a robust reduction in systolic BP in stage 4 CKD. In this study, we explore the mechanisms underlying the antihypertensive effect of CTD. Methods: In this prespecified analysis, we analyzed the contributions of baseline levels of 24-hour urinary sodium and aldosterone and the changes from baseline to 4 weeks in the multiple mediators reflecting volume status in a causal mediation analysis framework. Baseline levels of these mediators served as covariates. No power calculation for this analysis was performed. Results: Of the 160 patients randomized, 140 (87.5%) were included in this analysis. Compared with placebo, CTD within 4 weeks reduced weight −1.5% (95% confidence interval [CI], −2.2 to −0.7) and volume −1.4% (95% CI, −2.2 to −0.6), stimulated plasma renin 40.5% (95% CI, 25.4% to 57.4%) and serum aldosterone 40.2% (95% CI, 11.7% to 76%), and reduced plasma N-terminal pro-B-type natriuretic peptide levels −19.4% (95% CI, −33.8% to −1.9%). Mediation analysis revealed the following results: for weight change, the total effect on systolic BP was −10.8 mm Hg (95% CI, −16 to −5.7), of which weight change (indirect effect) accounted for −0.9 mm Hg (95% CI, −4.2 to 2.5) and BP change independent of weight (direct effect) accounted for −10 mm Hg (−15.7 to −4.2). Thus, the percent mediation was 8.1% (95% CI, −22.4 to 38.5). Baseline excretion of 24-hour sodium or aldosterone or any of the changes in the above mediators examined accounted for N-terminal pro-B-type natriuretic peptide. Clinical Trial registry name and registration number: CTD in chronic kidney disease ClinicalTrials.gov number: NCT02841280.
- 12 June 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19  (8) , 1025-1032
Mechanisms of Antihypertensive Effect of Chlorthalidone in Advanced Chronic Kidney Disease
Key Points: Chlorthalidone reduces the amount of fluid and the BP, but fluid volume reduction is not the cause of lowering of BP. It is not volume loss but the response to volume loss such as the synthesis of substances that lower BP is important. Background: Chlorthalidone (CTD) in a chronic kidney disease randomized trial demonstrated a robust reduction in systolic BP in stage 4 CKD. In this study, we explore the mechanisms underlying the antihypertensive effect of CTD. Methods: In this prespecified analysis, we analyzed the contributions of baseline levels of 24-hour urinary sodium and aldosterone and the changes from baseline to 4 weeks in the multiple mediators reflecting volume status in a causal mediation analysis framework. Baseline levels of these mediators served as covariates. No power calculation for this analysis was performed. Results: Of the 160 patients randomized, 140 (87.5%) were included in this analysis. Compared with placebo, CTD within 4 weeks reduced weight −1.5% (95% confidence interval [CI], −2.2 to −0.7) and volume −1.4% (95% CI, −2.2 to −0.6), stimulated plasma renin 40.5% (95% CI, 25.4% to 57.4%) and serum aldosterone 40.2% (95% CI, 11.7% to 76%), and reduced plasma N-terminal pro-B-type natriuretic peptide levels −19.4% (95% CI, −33.8% to −1.9%). Mediation analysis revealed the following results: for weight change, the total effect on systolic BP was −10.8 mm Hg (95% CI, −16 to −5.7), of which weight change (indirect effect) accounted for −0.9 mm Hg (95% CI, −4.2 to 2.5) and BP change independent of weight (direct effect) accounted for −10 mm Hg (−15.7 to −4.2). Thus, the percent mediation was 8.1% (95% CI, −22.4 to 38.5). Baseline excretion of 24-hour sodium or aldosterone or any of the changes in the above mediators examined accounted for N-terminal pro-B-type natriuretic peptide. Clinical Trial registry name and registration number: CTD in chronic kidney disease ClinicalTrials.gov number: NCT02841280.
- 15 June 2023
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 29  (10) , 1471-1472
Response: Letter to the Editor
- 15 June 2023
- Published by Elsevier in Journal of Cardiac Failure
- Vol. 29  (10) , 1471-1472
Response: Letter to the Editor
- 12 May 2021
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 6  (7) , 849-850
Transthyretin Genetic Testing
A 40-year-old woman recently participated in a research study that incidentally identified a pathogenic variant in the transthyretin (TTR) (OMIM 176300) gene. She was reported to have a single heterozygous nucleotide variant leading to substitution of serine for tyrosine at amino acid position 97 (Ser97Tyr, SNP rs267607161). The patient is of European descent, and her medical history was notable for carpal tunnel syndrome. She was asymptomatic from a cardiopulmonary standpoint. She reported no family history of amyloidosis, but her paternal grandfather died of heart disease at age 52 years. Her physical examination results showed a blood pressure of 112/76 mm Hg and heart rate of 79/min. Her cardiovascular examination results were unremarkable, with a jugular venous pressure of 5 cm H2O, no lower extremity edema, and normal heart sounds. Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.
- 12 May 2021
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 6  (7) , 849-850
Transthyretin Genetic Testing
A 40-year-old woman recently participated in a research study that incidentally identified a pathogenic variant in the transthyretin (TTR) (OMIM 176300) gene. She was reported to have a single heterozygous nucleotide variant leading to substitution of serine for tyrosine at amino acid position 97 (Ser97Tyr, SNP rs267607161). The patient is of European descent, and her medical history was notable for carpal tunnel syndrome. She was asymptomatic from a cardiopulmonary standpoint. She reported no family history of amyloidosis, but her paternal grandfather died of heart disease at age 52 years. Her physical examination results showed a blood pressure of 112/76 mm Hg and heart rate of 79/min. Her cardiovascular examination results were unremarkable, with a jugular venous pressure of 5 cm H2O, no lower extremity edema, and normal heart sounds. Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.
- Open Access
Implementation of a Renal Precision Medicine Program: Clinician Attitudes and Acceptance
A precision health initiative was implemented across a multi-hospital health system, wherein a panel of genetic variants was tested and utilized in the clinical care of chronic kidney disease (CKD) patients. Pharmacogenomic predictors of antihypertensive response and genomic predictors of CKD were provided to clinicians caring for nephrology patients. To assess clinician knowledge, attitudes, and willingness to act on genetic testing results, a Likert-scale survey was sent to and self-administered by these nephrology providers (N = 76). Most respondents agreed that utilizing pharmacogenomic-guided antihypertensive prescribing is valuable (4.0 ± 0.7 on a scale of 1 to 5, where 5 indicates strong agreement). However, the respondents also expressed reluctance to use genetic testing for CKD risk stratification due to a perceived lack of supporting evidence (3.2 ± 0.9). Exploratory sub-group analyses associated this reluctance with negative responses to both knowledge and attitude discipline questions, thus suggesting reduced exposure to and comfort with genetic information. Given the evolving nature of genomic implementation in clinical care, further education is warranted to help overcome these perception barriers.
Open AccessImplementation of a Renal Precision Medicine Program: Clinician Attitudes and Acceptance
A precision health initiative was implemented across a multi-hospital health system, wherein a panel of genetic variants was tested and utilized in the clinical care of chronic kidney disease (CKD) patients. Pharmacogenomic predictors of antihypertensive response and genomic predictors of CKD were provided to clinicians caring for nephrology patients. To assess clinician knowledge, attitudes, and willingness to act on genetic testing results, a Likert-scale survey was sent to and self-administered by these nephrology providers (N = 76). Most respondents agreed that utilizing pharmacogenomic-guided antihypertensive prescribing is valuable (4.0 ± 0.7 on a scale of 1 to 5, where 5 indicates strong agreement). However, the respondents also expressed reluctance to use genetic testing for CKD risk stratification due to a perceived lack of supporting evidence (3.2 ± 0.9). Exploratory sub-group analyses associated this reluctance with negative responses to both knowledge and attitude discipline questions, thus suggesting reduced exposure to and comfort with genetic information. Given the evolving nature of genomic implementation in clinical care, further education is warranted to help overcome these perception barriers.
- Open Access
- 25 June 2019
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 3  (2) , e13558
The Feasibility of a Using a Smart Button Mobile Health System to Self-Track Medication Adherence and Deliver Tailored Short Message Service Text Message Feedback
Background: As many as 50% of people experience medication nonadherence, yet studies for detecting nonadherence and delivering real-time interventions to improve adherence are lacking. Mobile health (mHealth) technologies show promise to track and support medication adherence. Objective: The study aimed to evaluate the feasibility and acceptability of using an mHealth system for medication adherence tracking and intervention delivery. The mHealth system comprises a smart button device to self-track medication taking, a companion smartphone app, a computer algorithm used to determine adherence and then deliver a standard or tailored SMS (short message service) text message on the basis of timing of medication taking. Standard SMS text messages indicated that the smartphone app registered the button press, whereas tailored SMS text messages encouraged habit formation and systems thinking on the basis of the timing the medications were taken. Methods: A convenience sample of 5 adults with chronic kidney disease (CKD), who were prescribed antihypertensive medication, participated in a 52-day longitudinal study. The study was conducted in 3 phases, with a standard SMS text message sent in phases 1 (study days 1-14) and 3 (study days 46-52) and tailored SMS text messages sent during phase 2 (study days 15-45) in response to participant medication self-tracking. Medication adherence was measured using: (1) the smart button and (2) electronic medication monitoring caps. Concordance between these 2 methods was evaluated using percentage of measurements made on the same day and occurring within ±5 min of one another. Acceptability was evaluated using qualitative feedback from participants. Results: A total of 5 patients with CKD, stages 1-4, were enrolled in the study, with the majority being men (60%), white (80%), and Hispanic/Latino (40%) of middle age (52.6 years, SD 22.49; range 20-70). The mHealth system was successfully initiated in the clinic setting for all enrolled participants. Of the expected 260 data points, 36.5% (n=95) were recorded with the smart button and 76.2% (n=198) with electronic monitoring. Concordant events (n=94), in which events were recorded with both the smart button and electronic monitoring, occurred 47% of the time and 58% of these events occurred within ±5 min of one another. Participant comments suggested SMS text messages were encouraging. Conclusions: It was feasible to recruit participants in the clinic setting for an mHealth study, and our system was successfully initiated for all enrolled participants. The smart button is an innovative way to self-report adherence data, including date and timing of medication taking, which were not previously available from measures that rely on recall of adherence. Although the selected smart button had poor concordance with electronic monitoring caps, participants were willing to use it to self-track medication adherence, and they found the mHealth system acceptable to use in most cases.
- 25 June 2019
- Published by JMIR Publications Inc. in JMIR Formative Research
- Vol. 3  (2) , e13558
Open AccessThe Feasibility of a Using a Smart Button Mobile Health System to Self-Track Medication Adherence and Deliver Tailored Short Message Service Text Message Feedback
Background: As many as 50% of people experience medication nonadherence, yet studies for detecting nonadherence and delivering real-time interventions to improve adherence are lacking. Mobile health (mHealth) technologies show promise to track and support medication adherence. Objective: The study aimed to evaluate the feasibility and acceptability of using an mHealth system for medication adherence tracking and intervention delivery. The mHealth system comprises a smart button device to self-track medication taking, a companion smartphone app, a computer algorithm used to determine adherence and then deliver a standard or tailored SMS (short message service) text message on the basis of timing of medication taking. Standard SMS text messages indicated that the smartphone app registered the button press, whereas tailored SMS text messages encouraged habit formation and systems thinking on the basis of the timing the medications were taken. Methods: A convenience sample of 5 adults with chronic kidney disease (CKD), who were prescribed antihypertensive medication, participated in a 52-day longitudinal study. The study was conducted in 3 phases, with a standard SMS text message sent in phases 1 (study days 1-14) and 3 (study days 46-52) and tailored SMS text messages sent during phase 2 (study days 15-45) in response to participant medication self-tracking. Medication adherence was measured using: (1) the smart button and (2) electronic medication monitoring caps. Concordance between these 2 methods was evaluated using percentage of measurements made on the same day and occurring within ±5 min of one another. Acceptability was evaluated using qualitative feedback from participants. Results: A total of 5 patients with CKD, stages 1-4, were enrolled in the study, with the majority being men (60%), white (80%), and Hispanic/Latino (40%) of middle age (52.6 years, SD 22.49; range 20-70). The mHealth system was successfully initiated in the clinic setting for all enrolled participants. Of the expected 260 data points, 36.5% (n=95) were recorded with the smart button and 76.2% (n=198) with electronic monitoring. Concordant events (n=94), in which events were recorded with both the smart button and electronic monitoring, occurred 47% of the time and 58% of these events occurred within ±5 min of one another. Participant comments suggested SMS text messages were encouraging. Conclusions: It was feasible to recruit participants in the clinic setting for an mHealth study, and our system was successfully initiated for all enrolled participants. The smart button is an innovative way to self-report adherence data, including date and timing of medication taking, which were not previously available from measures that rely on recall of adherence. Although the selected smart button had poor concordance with electronic monitoring caps, participants were willing to use it to self-track medication adherence, and they found the mHealth system acceptable to use in most cases.
- Open Access
- 10 February 2019
- Published by JMIR Publications Inc. in JMIR Preprints
The Feasibility of a Using a Smart Button Mobile Health System to Self-Track Medication Adherence and Deliver Tailored Short Message Service Text Message Feedback (Preprint)
BACKGROUND As many as 50% of people experience medication nonadherence, yet studies for detecting nonadherence and delivering real-time interventions to improve adherence are lacking. Mobile health (mHealth) technologies show promise to track and support medication adherence. OBJECTIVE The study aimed to evaluate the feasibility and acceptability of using an mHealth system for medication adherence tracking and intervention delivery. The mHealth system comprises a smart button device to self-track medication taking, a companion smartphone app, a computer algorithm used to determine adherence and then deliver a standard or tailored SMS (short message service) text message on the basis of timing of medication taking. Standard SMS text messages indicated that the smartphone app registered the button press, whereas tailored SMS text messages encouraged habit formation and systems thinking on the basis of the timing the medications were taken. METHODS A convenience sample of 5 adults with chronic kidney disease (CKD), who were prescribed antihypertensive medication, participated in a 52-day longitudinal study. The study was conducted in 3 phases, with a standard SMS text message sent in phases 1 (study days 1-14) and 3 (study days 46-52) and tailored SMS text messages sent during phase 2 (study days 15-45) in response to participant medication self-tracking. Medication adherence was measured using: (1) the smart button and (2) electronic medication monitoring caps. Concordance between these 2 methods was evaluated using percentage of measurements made on the same day and occurring within ±5 min of one another. Acceptability was evaluated using qualitative feedback from participants. RESULTS A total of 5 patients with CKD, stages 1-4, were enrolled in the study, with the majority being men (60%), white (80%), and Hispanic/Latino (40%) of middle age (52.6 years, SD 22.49; range 20-70). The mHealth system was successfully initiated in the clinic setting for all enrolled participants. Of the expected 260 data points, 36.5% (n=95) were recorded with the smart button and 76.2% (n=198) with electronic monitoring. Concordant events (n=94), in which events were recorded with both the smart button and electronic monitoring, occurred 47% of the time and 58% of these events occurred within ±5 min of one another. Participant comments suggested SMS text messages were encouraging. CONCLUSIONS It was feasible to recruit participants in the clinic setting for an mHealth study, and our system was successfully initiated for all enrolled participants. The smart button is an innovative way to self-report adherence data, including date and timing of medication taking, which were not previously available from measures that rely on recall of adherence. Although the selected smart button had poor concordance with electronic monitoring caps, participants were willing to use it to self-track medication adherence, and they found the mHealth system acceptable to use in most cases.
- 10 February 2019
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessThe Feasibility of a Using a Smart Button Mobile Health System to Self-Track Medication Adherence and Deliver Tailored Short Message Service Text Message Feedback (Preprint)
BACKGROUND As many as 50% of people experience medication nonadherence, yet studies for detecting nonadherence and delivering real-time interventions to improve adherence are lacking. Mobile health (mHealth) technologies show promise to track and support medication adherence. OBJECTIVE The study aimed to evaluate the feasibility and acceptability of using an mHealth system for medication adherence tracking and intervention delivery. The mHealth system comprises a smart button device to self-track medication taking, a companion smartphone app, a computer algorithm used to determine adherence and then deliver a standard or tailored SMS (short message service) text message on the basis of timing of medication taking. Standard SMS text messages indicated that the smartphone app registered the button press, whereas tailored SMS text messages encouraged habit formation and systems thinking on the basis of the timing the medications were taken. METHODS A convenience sample of 5 adults with chronic kidney disease (CKD), who were prescribed antihypertensive medication, participated in a 52-day longitudinal study. The study was conducted in 3 phases, with a standard SMS text message sent in phases 1 (study days 1-14) and 3 (study days 46-52) and tailored SMS text messages sent during phase 2 (study days 15-45) in response to participant medication self-tracking. Medication adherence was measured using: (1) the smart button and (2) electronic medication monitoring caps. Concordance between these 2 methods was evaluated using percentage of measurements made on the same day and occurring within ±5 min of one another. Acceptability was evaluated using qualitative feedback from participants. RESULTS A total of 5 patients with CKD, stages 1-4, were enrolled in the study, with the majority being men (60%), white (80%), and Hispanic/Latino (40%) of middle age (52.6 years, SD 22.49; range 20-70). The mHealth system was successfully initiated in the clinic setting for all enrolled participants. Of the expected 260 data points, 36.5% (n=95) were recorded with the smart button and 76.2% (n=198) with electronic monitoring. Concordant events (n=94), in which events were recorded with both the smart button and electronic monitoring, occurred 47% of the time and 58% of these events occurred within ±5 min of one another. Participant comments suggested SMS text messages were encouraging. CONCLUSIONS It was feasible to recruit participants in the clinic setting for an mHealth study, and our system was successfully initiated for all enrolled participants. The smart button is an innovative way to self-report adherence data, including date and timing of medication taking, which were not previously available from measures that rely on recall of adherence. Although the selected smart button had poor concordance with electronic monitoring caps, participants were willing to use it to self-track medication adherence, and they found the mHealth system acceptable to use in most cases.
- 13 October 2016
- Published by Springer Nature
- p. 133-166
Hypertension in the Dialysis Patient